These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25534390)

  • 41. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.
    Narod SA; Lubinski J; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Rosen B; Kim-Sing C; Isaacs C; Domchek S; Sun P;
    Lancet Oncol; 2006 May; 7(5):402-6. PubMed ID: 16648044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results.
    Sardanelli F; Podo F; Santoro F; Manoukian S; Bergonzi S; Trecate G; Vergnaghi D; Federico M; Cortesi L; Corcione S; Morassut S; Di Maggio C; Cilotti A; Martincich L; Calabrese M; Zuiani C; Preda L; Bonanni B; Carbonaro LA; Contegiacomo A; Panizza P; Di Cesare E; Savarese A; Crecco M; Turchetti D; Tonutti M; Belli P; Maschio AD;
    Invest Radiol; 2011 Feb; 46(2):94-105. PubMed ID: 21139507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast magnetic resonance imaging for screening high-risk women.
    Sung JS; Dershaw DD
    Magn Reson Imaging Clin N Am; 2013 Aug; 21(3):509-17. PubMed ID: 23928241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Practicalities of developing a breast magnetic resonance imaging screening service for women at high risk for breast cancer.
    Kiely BE; Hossack LK; Shadbolt CL; Davis A; Cassumbhoy R; Moodie K; Antill Y; Mitchell G
    ANZ J Surg; 2011 Oct; 81(10):688-93. PubMed ID: 22295308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
    Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
    Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers.
    Huo Z; Giger ML; Olopade OI; Wolverton DE; Weber BL; Metz CE; Zhong W; Cummings SA
    Radiology; 2002 Nov; 225(2):519-26. PubMed ID: 12409590
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer.
    Lord SJ; Lei W; Craft P; Cawson JN; Morris I; Walleser S; Griffiths A; Parker S; Houssami N
    Eur J Cancer; 2007 Sep; 43(13):1905-17. PubMed ID: 17681781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients.
    Mann RM; Bult P; van Laarhoven HW; Span PN; Schlooz M; Veltman J; Hoogerbrugge N
    Eur J Radiol; 2013 Sep; 82(9):1416-22. PubMed ID: 23567481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
    Grann VR; Patel PR; Jacobson JS; Warner E; Heitjan DF; Ashby-Thompson M; Hershman DL; Neugut AI
    Breast Cancer Res Treat; 2011 Feb; 125(3):837-47. PubMed ID: 20644999
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
    Leach MO; Boggis CR; Dixon AK; Easton DF; Eeles RA; Evans DG; Gilbert FJ; Griebsch I; Hoff RJ; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Thompson D; Warren RM;
    Lancet; 2005 May 21-27; 365(9473):1769-78. PubMed ID: 15910949
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.
    Passaperuma K; Warner E; Causer PA; Hill KA; Messner S; Wong JW; Jong RA; Wright FC; Yaffe MJ; Ramsay EA; Balasingham S; Verity L; Eisen A; Curpen B; Shumak R; Plewes DB; Narod SA
    Br J Cancer; 2012 Jun; 107(1):24-30. PubMed ID: 22588560
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers.
    Ghunaim H; Laenen A; De Keyzer F; Soens J; Keupers M; Postema S; Neven P; Van Ongeval C
    Eur J Radiol; 2022 Jan; 146():110074. PubMed ID: 34902667
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.
    Vreemann S; Gubern-Mérida A; Schlooz-Vries MS; Bult P; van Gils CH; Hoogerbrugge N; Karssemeijer N; Mann RM
    Radiology; 2018 Feb; 286(2):443-451. PubMed ID: 29040037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.
    Warner E; Messersmith H; Causer P; Eisen A; Shumak R; Plewes D
    Ann Intern Med; 2008 May; 148(9):671-9. PubMed ID: 18458280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Breast cancer screening in BRCA1/2 pathogenic sequence variant carriers during pregnancy and lactation.
    Sorin V; Bufman H; Bernstein-Molho R; Faermann R; Friedman E; Raskin D; Balint Lahat N; Sklair-Levy M
    Clin Imaging; 2024 Jul; 111():110189. PubMed ID: 38759599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
    Calderon-Margalit R; Paltiel O
    Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Breast cancer surveillance in BRCA positive Sri Lankan women: health equity for a high-risk group at a limited resource setting.
    Liyanage UA; Sirisena ND; Deshapriya PC; Dissanayake VHW
    BMC Womens Health; 2023 Nov; 23(1):636. PubMed ID: 38017478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
    Murakami W; Tozaki M; Nakamura S; Ide Y; Inuzuka M; Hirota Y; Murakami K; Takahama N; Ohgiya Y; Gokan T
    Breast Cancer; 2019 Sep; 26(5):552-561. PubMed ID: 30820924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.